Stocktwits on MSN

MRNA vs. NVAX: Which vaccine stock is Wall Street more bullish on right now?

Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and ...

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza ...
Investopedia

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Moderna shares up 2% as skin cancer vaccine shows sustained benefit in five-year follow-up

Moderna and Merck said on Tuesday their ⁠experimental personalized vaccine continued to cut the risk of death or recurrence ...

How New Institutional Interest and Vaccine Approvals Could Reshape Zoetis’ (ZTS) Investment Narrative

In 2025, Fundsmith Equity Fund began building a position in Zoetis, while the company reported third-quarter revenue growth ...
Nasdaq

Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules

Per several third-party articles, Dr. Vinay Prasad — who heads the FDA’s Center for Biologics Evaluation and Research (CBER) — reportedly sent an internal memo to staffers on Friday acknowledging that ...